<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01888328</url>
  </required_header>
  <id_info>
    <org_study_id>AAI-US-102</org_study_id>
    <nct_id>NCT01888328</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fed Condition</brief_title>
  <official_title>An Open Label, Randomized, Single Dose, Oral Bioequivalence Study of Isotretinoin Capsules 40 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of ACCUTANEÂ® Capsules 40 mg of Roche Laboratories Inc., Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics and bioequivalence of
      isotretinoin formulations after administration of single doses to normal, non-smoking,healthy
      males under fed conditions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, randomized, two-treatment, single dose, oral bioequivalence study of
      Isotretinoin capsules 40 mg of Dr. Reddy's Laboratories Limited,under fed conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">June 2001</completion_date>
  <primary_completion_date type="Actual">May 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>Pre-dose (0) and 0.5, 1,1.5,2,2.5,3,4,5,6,7,8,11,14,18, 24,36,48,72 and 96 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Isotretinoin capsules, 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACCUTANE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACCUTANE 40 mg of Roche Laboratories Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Isotretinoin Capsules,40 mg</description>
    <arm_group_label>Isotretinoin capsules, 40 mg</arm_group_label>
    <arm_group_label>ACCUTANE</arm_group_label>
    <other_name>ACCUTANE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males between 18 and 45 years of age inclusive.

          2. Informed of the nature of the study and given written informed consent.

          3. Have a body weight within 15% of the appropriate range as defined in the 1983
             Metropolitan Life Company tables and weighing at least 125 lbs. (Appendix I).

        Exclusion Criteria

          1. Hypersensitivity to isotretinoin or related compounds.

          2. Any history of a clinical condition which might affect drug absorption, metabolism or
             excretion.

          3. Recent history of mental illness, drug addiction, drug abuse or alcoholism.

          4. Donation of greater than 500 ml of blood in the past 4 weeks prior to study dosing or
             difficulty in donating blood.

          5. Received an investigational drug within the 4 weeks prior to study dosing.

          6. Currently taking any prescription medication within the 7 days prior to study dosing
             or over-the-counter medication within 3 days of study dosing. This prohibition does
             not include vitamins or herbal preparations taken as nutritional supplements for
             non-therapeutic indications as judged by the attending physician.

          7. Regular tobacco use in the 3 months prior to study dosing.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Ralph Scallion , MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AAI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AAI</name>
      <address>
        <city>Quadrangle Drive, Chapel Hill,</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2013</study_first_posted>
  <last_update_submitted>June 26, 2013</last_update_submitted>
  <last_update_submitted_qc>June 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

